vs
MERCANTILE BANK CORP（MBWM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是MERCANTILE BANK CORP的1.9倍（$127.1M vs $67.6M），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.1%）
泰米尔纳德商业银行（TMB）是一家印度银行，总部位于泰米尔纳德邦杜蒂戈林。该行始建于1921年，最初名为纳达尔银行，1962年11月更名为泰米尔纳德商业银行，以拓展纳达尔社群以外的业务。目前该银行在印度全境拥有600家全功能网点、12个区域办事处及各类配套服务中心与自助设施。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MBWM vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.9倍
$67.6M
两年增速更快
ZLAB
近两年复合增速
9.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.6M | $127.1M |
| 净利润 | $22.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 33.6% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 16.1% | — |
| 每股收益（稀释后） | $1.32 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MBWMZLAB
| Q1 26 | $67.6M | — | ||
| Q4 25 | $62.1M | $127.1M | ||
| Q3 25 | $62.4M | $115.4M | ||
| Q2 25 | $60.9M | $109.1M | ||
| Q1 25 | $57.3M | $105.7M | ||
| Q4 24 | $58.5M | $108.5M | ||
| Q3 24 | $58.0M | $101.8M | ||
| Q2 24 | $56.8M | $100.1M |
净利润MBWMZLAB
| Q1 26 | $22.7M | — | ||
| Q4 25 | $22.8M | — | ||
| Q3 25 | $23.8M | $-36.0M | ||
| Q2 25 | $22.6M | $-40.7M | ||
| Q1 25 | $19.5M | $-48.4M | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $19.6M | $-41.7M | ||
| Q2 24 | $18.8M | $-80.3M |
毛利率MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | 42.0% | -54.6% | ||
| Q3 25 | 44.0% | -42.3% | ||
| Q2 25 | 42.6% | -50.3% | ||
| Q1 25 | 42.0% | -53.3% | ||
| Q4 24 | 39.7% | -62.6% | ||
| Q3 24 | 42.4% | -66.6% | ||
| Q2 24 | 41.4% | -76.0% |
净利率MBWMZLAB
| Q1 26 | 33.6% | — | ||
| Q4 25 | 36.8% | — | ||
| Q3 25 | 38.1% | -31.2% | ||
| Q2 25 | 37.1% | -37.3% | ||
| Q1 25 | 34.1% | -45.8% | ||
| Q4 24 | 33.5% | — | ||
| Q3 24 | 33.8% | -40.9% | ||
| Q2 24 | 33.1% | -80.2% |
每股收益（稀释后）MBWMZLAB
| Q1 26 | $1.32 | — | ||
| Q4 25 | $1.41 | $-0.05 | ||
| Q3 25 | $1.46 | $-0.03 | ||
| Q2 25 | $1.39 | $-0.04 | ||
| Q1 25 | $1.21 | $-0.04 | ||
| Q4 24 | $1.20 | $-0.09 | ||
| Q3 24 | $1.22 | $-0.04 | ||
| Q2 24 | $1.17 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $1.5M | — |
| 股东权益账面价值 | $736.9M | $715.5M |
| 总资产 | $6.9B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
总债务MBWMZLAB
| Q1 26 | $1.5M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MBWMZLAB
| Q1 26 | $736.9M | — | ||
| Q4 25 | $724.9M | $715.5M | ||
| Q3 25 | $657.6M | $759.9M | ||
| Q2 25 | $631.5M | $791.7M | ||
| Q1 25 | $608.3M | $810.8M | ||
| Q4 24 | $584.5M | $840.9M | ||
| Q3 24 | $583.3M | $667.7M | ||
| Q2 24 | $551.2M | $704.2M |
总资产MBWMZLAB
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.8B | $1.2B | ||
| Q3 25 | $6.3B | $1.2B | ||
| Q2 25 | $6.2B | $1.2B | ||
| Q1 25 | $6.1B | $1.2B | ||
| Q4 24 | $6.1B | $1.2B | ||
| Q3 24 | $5.9B | $985.3M | ||
| Q2 24 | $5.6B | $987.4M |
负债/权益比MBWMZLAB
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | $-26.0M | ||
| Q3 25 | $23.1M | $-32.0M | ||
| Q2 25 | $-7.8M | $-31.0M | ||
| Q1 25 | $-3.0M | $-61.7M | ||
| Q4 24 | $101.1M | $-55.8M | ||
| Q3 24 | $-8.1M | $-26.8M | ||
| Q2 24 | $9.1M | $-42.2M |
自由现金流MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M |
自由现金流率MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% |
资本支出强度MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% |
现金转化率MBWMZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | -0.35× | — | ||
| Q1 25 | -0.15× | — | ||
| Q4 24 | 5.15× | — | ||
| Q3 24 | -0.41× | — | ||
| Q2 24 | 0.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MBWM
| Net Interest Income | $55.9M | 83% |
| Noninterest Income | $11.7M | 17% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
